Vertex Pharmaceuticals Incorporated
523.93USD
-11.2400 (-2.10%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on VRTX.
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 8.9B | 9.9B | 11.0B | 12.0B | 13.3B | 14.6B |
| Q1 | 2.1B | 2.4B | 2.7B | 2.8B | 3.0B | — |
| Q2 | 2.2B | 2.5B | 2.6B | 3.0B | 3.3B | — |
| Q3 | 2.3B | 2.5B | 2.8B | 3.1B | 3.4B | — |
| Q4 | 2.3B* | 2.5B* | 2.9B* | 3.2B* | 3.5B | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 12.82 | 13.89 | -2.08 | 15.32 | 17.88 | 20.42 |
| Q1 | 2.96 | 2.69 | 4.21 | 2.49 | 4.02 | — |
| Q2 | 3.13 | 3.52 | -13.92 | 3.99 | 4.31 | — |
| Q3 | 3.59 | 3.97 | 4.01 | 4.20 | .081 | — |
| Q4 | 3.16* |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
Revenue to net income
| 3.72* |
| 3.54* |
| 4.62* |
| 4.62 |
| — |
Debt level and coverage